Immupharma Share Discussion Threads

[marie1980] 15/2/2020 23:30

Also,

Nobby,

Have a read on LSe Board.

They think and trade exactly like me.

Invest now at dirt cheap price and exit just before read out.

Means block your money now for 2-3 years and get out around atleast 70-100p price minimum.

Can your shield give this much return in 2 years even after FDA approval ?!

Oh wait shield retracted from 200 to 158p with no joint collaboration.

[marie1980] 15/2/2020 23:18

Nobby,

Fancy a bet here or in metro ?

Metro my bet is > 200p on 26th
Here
IMM > 30p by December 2020

Fancy a bet ?

For IMM I am happy to give you higher odds

Please let me know and we can facilitate bet

[marie1980] 15/2/2020 23:13

see you are trying to bet with senti over at MTRO. I won a £1000 bet with him on OPTI at the end of January and we are now on a second double or quits. There is 2 weeks to go and the price is more than 50% above his level....so in all likliehood he will owe me £2000 in a couple of weeks time.

— fancy a bet with me on 26th Feb ?

My bet metro > 200p on 26th eod
I would facilitate bet.

I’ve £210K now riding on HEMO, IMM and Metro with maximum £102K on IMM.

Having said that, metro bank I’m super confident on

[brad44] 15/2/2020 22:49

Which counter of Boots do you currently work at? The only medical advice I believe you are allowed to give is for the consumption of Neurofen plus..

[nobbygnome] 15/2/2020 22:05

>> Marie

I see you are trying to bet with senti over at MTRO. I won a £1000 bet with him on OPTI at the end of January and we are now on a second double or quits. There is 2 weeks to go and the price is more than 50% above his level....so in all likliehood he will owe me £2000 in a couple of weeks time.

So he probably doesn't want to lose yet again which is why he won't bet with you!

[the stigologist] 15/2/2020 21:23

You are a failure and an idiot. You called this wrong before. Thankfully I didn't listen and was in for a decent rise. Definitely won't be listening to you again.

It's a shame you're so bitter and twisted about being proved wrong and missing out you have to stick around like a bad smell polluting this BB.

[nobbygnome] 15/2/2020 20:48

and 'hope' in yours.

Apologies for posting educated information. Strangely I assume that shareholders want to hear such information to help their decisions. I worked in the field for 28 years and have been in exactly this sort of meeting with the FDA. Ho hum.....

[marie1980] 15/2/2020 20:44

Nobby,

Bottomline.

So many If, guess and probably in your one short paragraph.

I think now you should stay away from scaremongering.

Everyone knows this will fly past 20p easily.

[nobbygnome] 15/2/2020 20:26

But to add a little about the motivations and approach of the FDA. In reality there is a compelling argument against doing the trial in the US. However, the FDA are really only concerned about safety. So if you can concoct a convincing enough argument, they will usually agree. After all a failed phase III doesn't cost them anything and in fact of course they make money from the fees the companies pay. So that is why in the balance of probability the trial probably will be approved whereas if it was really examined in great detail in a completely rational way, it probably wouldn't. Ultimately I guess that is the correct approach because as a regulator you want to ensure every possibly approach is tried especially for difficult indications like SLE!

[nobbygnome] 15/2/2020 20:20

Wrt post 35699 you need to do more than 'hope'

and wrt post 35700, the point is that the patient stratification (anti DNA ab positivity) didn't show anything close to statistical significance in the US cohort so why should it next time. The argument would be, well the numbers were so small you don't really know. However, the 'statistical significance' for that stratification was obtained on a similarly small group (the Europeans) so is it relevant or not? You can't have it both ways. I will tell you that is exactly what the FDA will be asking....

[marie1980] 15/2/2020 18:35

I don’t want to repeat all this and one everyone should agree that post FDA of P3 approval, share price will not stay at 15p.
Not even 20p:

Like you kept saying in shield board, that Sheild is risk free. Yes, I would agree but IMM perhaps give us the best opportunity make money.

[marie1980] 15/2/2020 18:33

Nobby,

One more.


IF the FDA agrees with IMM that the focus of the new Phase 3 should be on Lupus patients with the biomarker anti-dsDNA autoantibody positive I would feel confident that Lupuzor will reach its efficacy endpoint as happened with that same sub- group within the European cohort in the first Phase 3 trial. I would expect FDA approval to be very likely Maybe, too, the FDA will agree more specific measures of efficacy which will be helpful to IMM.

[marie1980] 15/2/2020 18:31

Nobby,

Before I repeat myself, Avion is on the side of IMM.

I’m copying these which will clear your concern.

I had not previously realised there was this destinction between the American patients and the Mauritian ones. I still find it very strange that the American patients who were on Lupuzor did not show a better outcome than those who were on SOC plus placebo. Even the IMM analysis of 28th May 2018 which showed the statistically significant favourable response of the European cohort which was treated with Lupuzor did not address the issue of the poor response in the American cohort who were on Lupuzor. And I have not come across any further info on the IMM website to indicate if further analysis has produced a scientific explanation for this strange resullt.
I hope the link with Avion will improve the selection of American patients for the new Phase 3 trial , and its supervision. Hopefully this will provide more realistic results than happened in the first Phase 3 trial.

[ken chung] 15/2/2020 18:27

Lemmings and mushrooms only.

[nobbygnome] 15/2/2020 18:21

>> Marie

Whatever your confidence, there is some doubt considering the trial history of Lupuzor. Remember it has never met a primary endpoint in any trial. It is definitely not a foregone conclusion. Better than 50:50 chance yes, but foregone conclusion definitely not. I have been in similar FDA meetings so know a little about which I speak.

[marie1980] 15/2/2020 18:16

Flavio,

Suggest you to read LSE board.
I remember you accused me that I’m here till P3 read out.

Look like me most of members are here to invest for 2-3 years and get out right before p3 read out.

Having said that, investing around 15p now and waiting for 2-3 years could be the bbest investment I would suggest for anyone.


IMM at this level is no brainer.

Nobby suggested earlier that he has doubt whether FDA approved p3 trial or not. But I’m absolutely confident they will and considering IMM has now full backing of Avion, I’ve now no doubt that IMM will trade atleast in 50s in 2 years of time.

Comments ?

[marie1980] 14/2/2020 20:00

Reported..

[dplewis1] 14/2/2020 19:24

Report them - ADVFN will have to do something about it eventually.

[master rsi] 14/2/2020 16:55

UT at 14.50p low of the day ( and at around the 61.8% retracement)

Funny how after 4pm the large trades took place, some of them are done during the day at a specific price, so they can be reported at the end of the day.

There was a few large buys at 14.50p at the end but the AT did not activate the offer side price 2X50k and 25K plus earlier the 120K @ 14.75p.

[master rsi] 14/2/2020 15:34

Needs some more help on the trades to get it going on, not much going on now for some time

[marie1980] 14/2/2020 15:09

Bingo Master!

[master rsi] 14/2/2020 14:56

It looks like the bounce is taking place on the chart